Title |
Novel Immunologic Approaches in Lymphoma: Unleashing the Brakes on the Immune System
|
---|---|
Published in |
Current Oncology Reports, May 2015
|
DOI | 10.1007/s11912-015-0456-y |
Pubmed ID | |
Authors |
Loretta J. Nastoupil, Sattva S. Neelapu |
Abstract |
Immunotherapy is a promising therapeutic strategy in the treatment of lymphoma. The programmed death-1 (PD-1)/PD-ligand immune checkpoint pathway has been manipulated by tumor cells and serves as a mechanism of tumor evasion from the anti-tumor immune response. The recent development of anti-PD-1 antibodies has offered a therapeutic strategy for restoring the function of exhausted antigen-specific T cells and enhancing the endogenous anti-tumor immunity. We review the clinical studies demonstrating efficacy and safety of PD-1 antibodies in relapsed/refractory Hodgkin, follicular, and diffuse large B cell lymphoma. Principles learned in the development of immune checkpoint blockade provide the foundation for immunotherapy under clinical investigation. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Korea, Republic of | 1 | 3% |
Unknown | 34 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 14 | 40% |
Student > Bachelor | 5 | 14% |
Student > Ph. D. Student | 3 | 9% |
Student > Doctoral Student | 2 | 6% |
Lecturer | 1 | 3% |
Other | 4 | 11% |
Unknown | 6 | 17% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 12 | 34% |
Agricultural and Biological Sciences | 4 | 11% |
Biochemistry, Genetics and Molecular Biology | 3 | 9% |
Immunology and Microbiology | 3 | 9% |
Chemistry | 2 | 6% |
Other | 3 | 9% |
Unknown | 8 | 23% |